Related Experiment Video
Updated: Jun 4, 2025
06:54
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
12.8K
End Binding Proteins: Drivers of Cancer Progression
Dhakshmi Sasankan1, Renu Mohan1
1Department of Biotechnology, University of Kerala, Kariavattom Campus, Thiruvananthapuram, India.
Cytoskeleton (Hoboken, N.J.)
|December 19, 2024
Summary
End Binding (EB) proteins are crucial regulators of microtubule dynamics. This review explores their role in cancer severity and aggressiveness, highlighting their potential as biomarkers and therapeutic targets.
Area of Science:
- Oncology
- Cell Biology
- Molecular Medicine
Background:
- Cancer remains a significant global health challenge, with aggressive subtypes posing a major hurdle.
- Cellular processes like migration, division, and shape changes, critical for cancer progression, are driven by dynamic microtubules.
- End Binding (EB) proteins are key regulators of microtubule dynamics at their growing plus ends.
Purpose of the Study:
- To comprehensively review the role of microtubule-associated EB proteins in cancer severity and aggressiveness.
- To discuss the potential of EB proteins as clinical biomarkers for cancer diagnosis and prognosis.
- To explore EB proteins as potential therapeutic targets for cancer intervention.
Main Methods:
- Literature review of studies investigating EB proteins and their association with cancer.
- Analysis of research on microtubule dynamics and their regulation by EB proteins in cancer cells.
- Synthesis of findings on the clinical implications of EB proteins in cancer.
Main Results:
- EB proteins critically influence microtubule dynamics, impacting cancer cell behaviors.
- Evidence links EB protein dysregulation to increased cancer severity and aggressiveness.
- EB proteins show promise as predictive biomarkers and therapeutic targets in oncology.
Conclusions:
- EB proteins are significant players in cancer progression, influencing disease severity and aggressiveness.
- Targeting EB proteins may offer novel therapeutic strategies for cancer treatment.
- EB proteins hold potential as valuable biomarkers for cancer diagnosis and prognosis.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
01:31The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
01:24Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
02:53Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K